Compare SRI & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRI | RNAC |
|---|---|---|
| Founded | 1965 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.4M | 238.9M |
| IPO Year | 1997 | 2016 |
| Metric | SRI | RNAC |
|---|---|---|
| Price | $7.22 | $8.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $16.00 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 104.5K | 101.9K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $824,444,000.00 | $2,797,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.46 | N/A |
| 52 Week Low | $4.60 | $5.60 |
| 52 Week High | $9.71 | $11.00 |
| Indicator | SRI | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 52.55 | 44.45 |
| Support Level | $7.26 | $8.80 |
| Resistance Level | $7.51 | $9.27 |
| Average True Range (ATR) | 0.23 | 0.62 |
| MACD | 0.03 | -0.14 |
| Stochastic Oscillator | 71.01 | 11.64 |
Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Geographically, the company generates key revenue from the United States.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.